ZX 9021
Alternative Names: ZX-9021Latest Information Update: 12 Jul 2022
At a glance
- Originator Nanjing Zenshine Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jul 2022 Preclinical trials in Cancer in China (unspecified route) (Nanjing Zenshine Pharmaceuticals pipeline, July 2022)